LONDON–(BUSINESS WIRE)–  Re: Mortimer 2024-Mix PLC   GBP 3,569,000.00   MATURING: 22-Sep-2067   ISIN: XS2920414971     PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 22-Jun-2026 TO 22-Sep-2026 HAS BEEN FIXED AT 7.48 PCT   DAY BASIS: ACTUAL/365(PROP)   INTEREST PAYABLE VALUE 22-Sep-2026 WILL AMOUNT TO: GBP 24,395.08 PER GBP 1,294,288.61 DENOMINATION  

LONDON–(BUSINESS WIRE)–  Re: Mortimer 2025-1 PLC   GBP 9,523,000.00   MATURING: 22-Sep-2070   ISIN: XS3196127347     PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 22-Jun-2026 TO 22-Sep-2026 HAS BEEN FIXED AT 5.30 PCT   DAY BASIS: ACTUAL/365(PROP)   INTEREST PAYABLE VALUE 22-Sep-2026 WILL AMOUNT TO: GBP 134,803.18 PER GBP 10,095,000.00 DENOMINATION  

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News: Bordeaux, Boston, le 15 septembre 2026 – 17h45 CEST : IMPLANET (Euronext Growth : ALIMP, FR0013470168, éligible au PEA-PME), société de technologies médicales spécialisée dans les implants destinés à la chirurgie orthopédique et dans la distribution de matériel médical technologique, annonce aujourd’hui ses résultats pour le premier semestre de l’exercice en cours, clos le 30 juin 2026, et arrêtés par le Conseil d’Administration du 15

PHILADELPHIA–(BUSINESS WIRE)– #BleuGarde–Bleu Garde, LLC, a science and technology company developing next-generation indoor air treatment technologies for pathogen reduction, environmental health and pandemic preparedness, today announced at the Builds Bio+ 5th Annual Philadelphia Life Science Symposium that the U.S. Environmental Protection Agency (EPA) has registered Arresta® for use as a virucidal air treatment, air sanitizer and fungistat, including use in occupied indoor spaces in accordance with i

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and in the distribution of advanced medical equipment, today announces its results for the first half of the current financial year, ended June 30, 2026, as approved by the Board of Directors on September 15, 2026. Ludovic Lastennet, IMPLANET’s Chief Executive Officer, stated: “The sustain

SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News: Median Technologies (FR0011049824, ALMDT, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI)-powered Software as Medical Devices (SaMD) for early cancer detection and diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today the signing of one of the largest projects in the Company’s history for its iCRO busi

SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News: Median Technologies (FR0011049824, ALMDT, éligible PEA/PME, « Median » ou « La Société »), développeur d’eyonis®, une suite de logiciels dispositifs médicaux basés sur l’intelligence artificielle (IA) pour la détection et le diagnostic précoces des cancers, et un leader mondial de la fourniture d’analyses d’images par IA et de services centraux d’imagerie pour les essais cliniques en oncologie de l’industrie biopharmaceutique, annonce

ANTWERPEN, België–(BUSINESS WIRE)–GEREGULEERDE INFORMATIE In overeenstemming met artikel 14 van de Belgische Transparantiewet van 2 mei 2007 maakt Azelis Group NV (Brussels:AZE) bekend dat het een transparantiekennisgeving heeft ontvangen van UBS Group AG op 10 september 2026. 1. Samenvatting van de kennisgeving UBS Group AG heeft in een kennisgeving gedateerd op 10 september 2026 gemeld dat op 8 september 2026, na een vervreemding van gelijkgestelde financiële instrumenten, UBS Group AG (rek

ANTWERP, Belgium–(BUSINESS WIRE)–REGULATED INFORMATION In accordance with Article 14 of the Belgian Transparency law of 2 May 2007, Azelis Group NV (Brussels:AZE) announces that on 10 September 2026, it has received a transparency notification from UBS Group AG. 1. Summary of the notification UBS Group AG reported in its notification dated 10 September 2026, that on 8 September 2026, following a disposal of equivalent financial instruments, UBS Group AG (taking into account the holding of all

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.